Corticosteroids — Mechanisms, Pharmacology, and Clinical Use

In the absence of ligand, the GR resides in the cytoplasm held in an inactive complex with heat shock proteins (including heat shock protein 90) that keep it sequestered and prevent inadvertent gene activation. GCs are lipophilic and freely cross the cell membrane. When a GC binds the GR, the heat shock protein complex dissociates, a nuclear localization signal is exposed, and the GC-GR complex is actively transported into the nucleus within minutes. This rapid nuclear entry is why the GR activation step itself is fast, even though the downstream transcriptional changes unfold over hours.

In the nucleus, the GC-GR complex can dimerize and bind to specific DNA sequences called glucocorticoid response elements in the promoter regions of target genes. This direct DNA binding (transactivation) upregulates genes whose protein products have anti-inflammatory roles. The most pharmacologically important transactivation target is annexin A1 (formerly called lipocortin-1), an endogenous inhibitor of PLA2. By inducing annexin A1, corticosteroids suppress the rate-limiting step in eicosanoid synthesis — the liberation of arachidonic acid from membrane phospholipids — blocking both the COX pathway and the LOX pathway simultaneously. This upstream PLA2 block is the critical mechanistic distinction from NSAIDs, which act downstream of PLA2 and block only the COX pathway.

Other transactivation targets include anti-inflammatory signaling proteins that dampen the inflammatory cascade at multiple points. However, transactivation also drives many of the metabolic side effects of corticosteroids: upregulation of gluconeogenic enzymes, promotion of lipolysis and adipose redistribution, and catabolism of muscle protein are all GRE-driven transactivation events.

The second nuclear mechanism — transrepression — does not require the GR to bind DNA directly. Instead, the activated GR tethers to pro-inflammatory transcription factors, principally NF-κB and AP-1, through protein-protein interactions. This tethering prevents NF-κB and AP-1 from binding to their target gene promoters, blocking transcription of a broad array of pro-inflammatory mediators: interleukin-1 beta, interleukin-2, interleukin-6, interleukin-8, tumor necrosis factor-alpha, COX-2, and matrix metalloproteinases. The suppression of COX-2 gene transcription by this mechanism adds a second layer of eicosanoid inhibition on top of the upstream PLA2 block from annexin A1 induction.

This combination — upstream PLA2 inhibition via annexin A1 and downstream COX-2 gene suppression via NF-κB transrepression — explains why corticosteroids are more potent anti-inflammatory agents than any NSAID at equivalent doses. NSAIDs can only block the COX enzyme; corticosteroids reduce the amount of arachidonic acid entering the pathway and simultaneously suppress the inducible COX-2 gene that produces the inflammatory enzyme in the first place.

Beyond eicosanoid suppression and cytokine gene transrepression, corticosteroids produce coordinated changes in leukocyte behavior that reduce inflammatory cell infiltration into tissues. Neutrophils are rapidly demarginated from vascular endothelium (because corticosteroids reduce adhesion molecule expression), causing a characteristic neutrophilia in the blood within hours of a corticosteroid dose. However, neutrophil migration into inflamed tissues is simultaneously reduced through suppression of chemokine production. The net effect is more circulating neutrophils but less tissue neutrophil infiltration.

Eosinophils are exquisitely sensitive to corticosteroids: circulating eosinophil counts fall within hours because corticosteroids promote eosinophil apoptosis and reduce the interleukin-5 and granulocyte-macrophage colony-stimulating factor survival signals that normally sustain them. This rapid eosinophil reduction is the basis for corticosteroids' effectiveness in eosinophilic asthma, allergic rhinitis, and eosinophilic esophagitis. Lymphocytes are redistributed from the bloodstream into lymphoid organs, producing lymphopenia; at high doses, lymphocyte apoptosis also occurs, contributing to immunosuppression. Vascular permeability is reduced through suppression of histamine release and downregulation of vascular endothelial growth factor, attenuating the edema component of inflammation.

In anaphylaxis, corticosteroids are given as adjunctive therapy after epinephrine — hydrocortisone or methylprednisolone intravenously — with the rationale of preventing or attenuating a biphasic anaphylactic reaction occurring hours after the initial event. Epinephrine remains the first and only essential drug in anaphylaxis; corticosteroids are supportive.

In acute severe asthma, systemic corticosteroids administered within the first hour of emergency presentation reduce hospital admission rates. Both intravenous methylprednisolone and oral prednisolone are effective and approximately equivalent in outcome when the oral route is feasible. The anti-inflammatory mechanism takes hours to manifest, so corticosteroids complement bronchodilators rather than replace them in the acute setting.

In giant cell arteritis, high-dose prednisone must be started immediately when the clinical picture is consistent with the diagnosis, without waiting for temporal artery biopsy results. The ophthalmic and posterior ciliary arteries supplying the retina can occlude from granulomatous inflammation, causing rapid and permanent vision loss. The biopsy should be performed within one to two weeks of starting corticosteroids — histological findings persist for this period despite steroid treatment.

In cerebral edema from brain tumors or metastases, dexamethasone is preferred because its negligible mineralocorticoid activity avoids sodium retention and because its long biological half-life enables twice-daily or four-times-daily dosing. Dexamethasone is ineffective in cytotoxic edema from ischemic stroke and should not be used in that setting.

Corticosteroids are used as induction therapy for many serious autoimmune and inflammatory conditions, typically followed by steroid-sparing immunosuppressive agents as maintenance. In systemic lupus erythematosus with nephritis or major organ involvement, high-dose prednisone combined with cyclophosphamide or mycophenolate is standard induction. In polymyalgia rheumatica, low-dose prednisone produces dramatic symptomatic relief within days — a response so characteristic that it serves as a diagnostic criterion. In autoimmune hemolytic anemia and immune thrombocytopenic purpura, prednisone at 1 mg per kg per day is first-line. In organ transplantation, corticosteroids remain a core component of immunosuppression protocols and first-line treatment for acute cellular rejection.

In primary adrenal insufficiency (Addison disease), both glucocorticoid and mineralocorticoid replacement are required. Hydrocortisone given in divided doses — approximately two-thirds in the morning and one-third in the early afternoon — mimics the normal diurnal cortisol pattern and avoids HPA axis suppression better than once-daily dosing. Fludrocortisone provides mineralocorticoid replacement. In secondary adrenal insufficiency from pituitary disease or exogenous corticosteroid withdrawal, mineralocorticoid replacement is not required because aldosterone secretion via the renin-angiotensin-aldosterone system is intact. All patients with adrenal insufficiency require sick day rules education and an emergency injectable hydrocortisone kit.

ICS achieve high local airway concentrations while minimizing systemic exposure through two complementary pharmacokinetic features. First, inhaled particles deposit drug directly on inflamed airway mucosa, producing high local concentrations with a small administered dose. Second, the fraction of drug that reaches systemic circulation — from both pulmonary absorption and swallowed oropharyngeal drug — undergoes rapid first-pass hepatic metabolism by CYP3A4, limiting systemic bioavailability. Fluticasone propionate and fluticasone furoate have essentially zero oral bioavailability due to near-complete hepatic first-pass extraction; the oropharyngeal fraction that is swallowed contributes negligibly to systemic exposure. This pharmacokinetic design gives ICS a therapeutic window that is far wider than equivalent systemic doses.

ICS are the cornerstone of chronic asthma management. They reduce airway inflammation, decrease exacerbation frequency, and improve symptom control across all levels of asthma severity requiring maintenance therapy. At higher asthma severity steps, ICS are combined with a LABA — a combination that is more effective than doubling the ICS dose, because LABAs and corticosteroids are pharmacologically synergistic: LABAs enhance GR nuclear translocation and corticosteroid responsiveness, while corticosteroids prevent the LABA-induced beta-2 receptor downregulation that would otherwise limit bronchodilator efficacy. LABAs must never be used as asthma monotherapy without an ICS — clinical trial evidence demonstrates increased asthma mortality with LABA alone.

In COPD, the role of ICS is more restricted. Triple inhaled therapy combining an ICS with a LABA and a long-acting muscarinic antagonist reduces exacerbation rates and mortality in patients with frequent exacerbations and blood eosinophil counts above 300 cells per microliter. Blood eosinophil count is a practical biomarker that predicts ICS responsiveness in COPD; ICS confer little benefit and increase pneumonia risk in COPD patients with low eosinophil counts.

Local adverse effects of ICS — oropharyngeal candidiasis and dysphonia — are reduced by using a spacer device, rinsing the mouth after each dose, and choosing prodrug ICS that are inactive at the oropharyngeal mucosa (such as ciclesonide).